(Invented) Name Review Group

The group's main role is to consider whether the (invented) name proposed by a product's manufacturer could create a public-health concern or potential safety risk.

This is part of EMA's role in evaluating the safety of medicinal products in the centralised marketing authorisation procedure.

In particular, the (invented) name should not:

• convey misleading therapeutic or pharmaceutical connotations;
• be misleading with respect to the composition of the product;
• be liable to cause confusion with the (invented) name of an existing medicinal product in print, handwriting or speech.

The group's responsibilities also include updating the relevant guideline on the acceptability of invented names.

The NRG is composed of representatives from Member States and is chaired by an Agency representative. Representatives of the European Commission and the Agency secretariat also participate in the work of the group. Other relevant experts, such as from the World Health Organization (WHO), are consulted on a case-by-case basis.

Below (in alphabetical order of surname) are the current attendees and contact points of the NRG. The members' declarations of interests are available in the European expert list.